Terms: = Pancreatic cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Prognosis
4 results:
1. Inhibition of xpo1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation.
Zhao C; Ma B; Yang ZY; Li O; Liu SL; Pan LJ; Gong W; Dong P; Shu YJ
Cancer Med; 2023 Mar; 12(5):5751-5763. PubMed ID: 36200270
[TBL] [Abstract] [Full Text] [Related]
2. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Vivaldi C; Caparello C; Musettini G; Pasquini G; Catanese S; Fornaro L; Lencioni M; Falcone A; Vasile E
Int J Cancer; 2016 Aug; 139(4):938-45. PubMed ID: 27038273
[TBL] [Abstract] [Full Text] [Related]
3. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.
Azmi AS; Aboukameel A; Bao B; Sarkar FH; Philip PA; Kauffman M; Shacham S; Mohammad RM
Gastroenterology; 2013 Feb; 144(2):447-456. PubMed ID: 23089203
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic value of crm1 in pancreas cancer.
Huang WY; Yue L; Qiu WS; Wang LW; Zhou XH; Sun YJ
Clin Invest Med; 2009 Dec; 32(6):E315. PubMed ID: 20003838
[TBL] [Abstract] [Full Text] [Related]
